Crops News Technology

Monsanto research now offers EXZACT genome-editing tech

Published:

A non-exclusive global option and licensing agreement between Monsanto and Dow AgroSciences hopes to put the next generation of crop improvements into farmers’ hands. Dow AgroSciences’ EXZACT Precision Technology Platform for research and commercial development of new crop solutions will now be available across Monsanto Company’s research portfolio.

EXZACT technology, which Dow AgroSciences has developed under an exclusive license and collaboration agreement in plants with Sangamo BioSciences, Inc., facilitates the creation of crop varieties and lines having improved traits.

“Monsanto is pleased to pursue applications of this genome-editing technology for the development of new plant discoveries and solutions for farmers,” said Tom Adams, Ph.D., biotechnology lead for Monsanto in a news release. “Zinc finger nucleases are a well-established technology for gene editing and this license, together with our existing and other licensed technology, will allow us to pursue product development while further enabling our growing body of research in this emerging field.”

Both companies noted that genome-editing technology and the broad array of emerging genome-editing techniques, including the zinc finger nuclease (ZFN) technology in EXZACT, represent key scientific applications that can deliver breakthroughs in agriculture. Monsanto believes that genome-editing technologies will enable plant breeders to deliver better hybrids and varieties more efficiently, as well as offer plant scientists additional resources to provide new improvements in plant biotechnology.

Any views or opinions expressed in this article are those of the author and do not reflect those of AGDAILY. Comments on this article reflect the sole opinions of their writers.